CJC-1295 UK: what is it and what does it actually do?

What is CJC-1295?

CJC-1295 is a synthetic version of growth-hormone-releasing hormone (GHRH). GHRH is one of the body’s own signals telling the pituitary gland to release growth hormone.

That makes CJC-1295 different from taking growth hormone itself. Rather than supplying GH directly, it is designed to stimulate the body’s own GH system. Growth hormone then influences the production of IGF-1, another hormone involved in growth, metabolism and tissue function.

This is why CJC-1295 now appears in conversations about muscle, recovery, body composition, sleep and anti-ageing. But there is an important distinction from the start: proving that a peptide raises GH and IGF-1 is not the same as proving that it builds muscle, burns fat or improves recovery.

If you are new to this area, our plain-English peptides guide explains where CJC-1295 fits alongside BPC-157, TB-500, ipamorelin and other peptides.

What does CJC-1295 actually do?

This is one peptide where we have controlled human evidence for the basic biological effect — at least for the original long-acting form.

In two randomized, double-blind, placebo-controlled studies in healthy adults, a single dose of long-acting CJC-1295 produced dose-dependent increases in average growth-hormone levels of around 2 to 10 times baseline for six days or more. Average IGF-1 levels increased by around 1.5 to 3 times baseline for 9 to 11 days.

The researchers estimated a half-life of about 5.8 to 8.1 days. After repeated doses, average IGF-1 remained above baseline for up to 28 days.

Those are real human results. What the studies did not establish was that participants gained significant muscle, lost body fat, recovered faster from injuries or experienced an anti-ageing effect. The trials were primarily looking at hormones, pharmacology and short-term safety.

Growth hormone and IGF-1: what does that actually mean?

Growth hormone gets talked about online as though more automatically means better. Human biology is not quite that simple.

GH is released by the pituitary gland and has effects throughout the body. One of its important actions is encouraging the liver and other tissues to produce IGF-1. Together, the GH–IGF-1 system is involved in growth, metabolism, bone, muscle and other tissues.

CJC-1295 is interesting because the original human trials clearly showed that it can push this system upwards for a sustained period. That gives the peptide a genuine biological effect rather than just a theoretical mechanism.

But hormone levels are what researchers call a surrogate outcome. A higher number in a blood test does not automatically tell us whether someone will become leaner, stronger, sleep better or recover faster. Those outcomes need to be tested directly.

CJC-1295 with DAC vs no DAC: the important difference

This is probably the most confusing part of CJC-1295 — and one of the most important.

The original CJC-1295 studied in people used a Drug Affinity Complex (DAC). The DAC modification allows the peptide to bind to albumin in the blood, dramatically extending how long it remains in circulation. That is the version behind the well-known human data showing a half-life of roughly a week and prolonged increases in GH and IGF-1.

You will also see products described as “CJC-1295 no DAC” or “without DAC”, often alongside the name Modified GRF 1-29. These are widely discussed as short-acting alternatives.

The evidence is not interchangeable. A 2026 review of performance-enhancing peptides concluded that CJC-1295 without DAC remains essentially uncharacterised in peer-reviewed human research, with no controlled clinical studies directly evaluating that compound in people.

So if you see the long half-life and human GH/IGF-1 figures quoted on a page selling “CJC-1295 no DAC”, be careful: those famous results came from the long-acting DAC-conjugated version.

Does CJC-1295 actually work in humans?

If by “work” you mean does the original long-acting CJC-1295 raise GH and IGF-1?, then yes — controlled human studies demonstrated that clearly.

If by “work” you mean does it build muscle, reduce body fat, speed recovery or slow ageing?, the evidence is much weaker.

The main human CJC-1295 trials were short pharmacology studies in healthy adults. They measured hormone concentrations and how long the compound remained active. They were not designed to establish meaningful changes in body composition, strength, sporting performance or long-term health.

This distinction matters because online discussions often take a proven first step — “CJC-1295 increases GH and IGF-1” — and treat all the claimed downstream benefits as though they were proven too. They are not.

CJC-1295 for muscle growth and recovery

The muscle and recovery claims are easy to understand. Growth hormone and IGF-1 are involved in tissue biology, so a compound that increases those hormones naturally attracts interest from bodybuilding and recovery communities.

But we still need direct evidence. The controlled CJC-1295 human trials did not show that healthy people gained more muscle, became stronger or recovered from training or injury faster.

A 2026 endocrine review examining peptides used for performance enhancement made the same point: CJC-1295 with DAC has human pharmacology data, but the evidence does not establish the physique and performance outcomes for which it is now commonly self-administered.

So the muscle-growth story remains biologically plausible rather than clinically proven.

Does CJC-1295 help with fat loss?

CJC-1295 also appears frequently in fat-loss and body-composition discussions because growth hormone influences fat metabolism.

Again, the problem is the jump from mechanism to outcome. The original controlled human studies showed sustained increases in GH and IGF-1, but they did not establish CJC-1295 as a weight-loss or fat-loss treatment.

There are medicines acting on the GH axis that have been studied for specific body-composition indications, but that evidence cannot simply be transferred to CJC-1295. Different compounds, patient groups and clinical endpoints matter.

So it is reasonable to say CJC-1295 affects hormones involved in metabolism. It is not reasonable to present it as a proven general-purpose fat-loss peptide.

CJC-1295 side effects and safety: what do we actually know?

The original short-term human trials reported that CJC-1295 was generally well tolerated in the doses studied, and no serious adverse reactions were reported in those small trials.

That is useful information, but it should not be stretched into “CJC-1295 is proven safe”. The studies were relatively small and lasted only weeks. They cannot tell us much about uncommon problems, long-term exposure or the safety of the peptide when used outside a controlled clinical study.

The 2026 endocrine review also notes safety concerns reported around CJC-1295 development, including vasodilatory reactions and tachycardia reports considered by US regulators.

There is another practical issue: products bought outside a regulated medicine supply chain may vary in identity, concentration, purity and sterility. That is separate from the safety of the molecule itself and makes real-world use harder to compare with controlled research.

The fairest summary is that we have some short-term human safety information for CJC-1295 with DAC, but not enough evidence to establish long-term safety — and considerably less direct information for products described as CJC-1295 without DAC.

Why are CJC-1295 and Ipamorelin used together?

CJC-1295 and ipamorelin are often discussed together because they stimulate growth-hormone release through different signalling systems.

CJC-1295 acts through the GHRH receptor. Ipamorelin is a growth-hormone secretagogue that acts through the ghrelin receptor. The online theory is that combining the two provides complementary stimulation of the GH system.

That mechanism explains why the pairing is popular. It does not prove that the combination produces better muscle growth, fat loss, sleep or recovery in healthy people.

There is a big difference between showing that two pathways can influence GH release and demonstrating meaningful long-term outcomes in a controlled clinical trial. We will cover ipamorelin separately in its own guide.

CJC-1295 and anti-ageing claims

CJC-1295 is sometimes described as an anti-ageing or longevity peptide because growth hormone levels generally decline with age.

That sounds persuasive, but a normal age-related change is not automatically something that becomes beneficial when reversed. The GH–IGF-1 system is complex, and both unusually low and unusually high signalling can have consequences.

There are no good clinical trials showing that CJC-1295 extends lifespan, reverses ageing or makes otherwise healthy people biologically younger.

For now, “anti-ageing peptide” is a marketing description rather than an established clinical use for CJC-1295.

CJC-1295 and sport: an important point for tested athletes

CJC-1295 is prohibited for athletes competing under World Anti-Doping Agency (WADA) rules.

WADA’s prohibited list includes growth-hormone-releasing hormone and its analogues, explicitly naming CJC-1295 among the prohibited growth-hormone-releasing factors. The current 2026 Prohibited List has been in force since 1 January 2026.

This applies regardless of whether the peptide is described online as being for recovery, sleep, body composition or “hormone optimisation”.

Anyone competing under anti-doping rules should check the current rules applying to their sport rather than relying on a supplier’s description.

CJC-1295 UK: where things stand right now

CJC-1295 is not licensed as a medicine in the UK. It remains an investigational peptide rather than an established treatment.

The evidence picture is more interesting than for many peptides because the original DAC-conjugated version genuinely has randomized, placebo-controlled human data showing prolonged increases in GH and IGF-1.

But that is also where the evidence needs to be kept in proportion. We know considerably more about the hormone response than we do about the outcomes people usually want from CJC-1295 — muscle gain, fat loss, recovery, sleep or anti-ageing.

And the increasingly common “CJC-1295 no DAC” category has a much thinner direct human evidence base than the original long-acting compound.

So in 2026, CJC-1295 is best described as an experimental GHRH analogue with a well-demonstrated hormonal effect for the DAC version, but without good clinical evidence proving the broader physique and anti-ageing claims attached to it online.

Frequently Asked Questions

Sources and editorial methodology

Page last reviewed: 23 August 2026. This guide was compiled by The Peptide Brief editorial team using peer-reviewed human research and official anti-doping sources. We distinguish the original DAC-conjugated CJC-1295 studied in people from products described as CJC-1295 without DAC, and we separate demonstrated hormone changes from unproven physique or performance claims.

Key sources:
Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006. Two randomized, placebo-controlled, double-blind trials demonstrated sustained increases in GH and IGF-1 after the DAC-conjugated form.
The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 2026. The review distinguishes CJC-1295 with DAC from the essentially uncharacterised no-DAC form and highlights the lack of controlled performance/body-composition outcomes.
World Anti-Doping Agency 2026 Prohibited List. CJC-1295 is prohibited as a growth-hormone-releasing factor.

We accept no payment, sponsorship or affiliate commission from peptide sellers or pharmaceutical manufacturers.
Spotted something out of date or incorrect? Email corrections@thepeptidebrief.co.uk and we will investigate.

This guide is for information and research purposes only and does not constitute medical advice. Do not start, stop or change any treatment based on information on this page.